本研究的目的是评估奥西美替尼治疗表皮生长因子受体（EGFR）突变非小细胞肺癌（NSCLC）脑膜转移（LM）的疗效和安全性。我们进行了系统回顾和荟萃分析，以汇总接受奥西美替尼治疗的EGFR突变NSCLC患者的临床结果。根据PRISMA指南，在2021年四月，我们在PubMed、EMBASE、Cochrane图书馆和其他多个国际会议数据库中进行了全面的文献检索，包括已发表和未发表的研究。采用比例的荟萃分析计算了总体反应率（ORR）、疾病控制率（DCR）、一年总生存率（OS）和不良事件（AEs）的汇总率。共纳入了11项研究（5项前瞻性和6项回顾性），包括353名患者。大多数患者（346/353，98.0%）接受奥西美替尼作为≥第二线的LM治疗，剂量分别为80 mg（161/353，45.6%）和160 mg（191/353，54.1%）。总体ORR和DCR的汇总率分别为42%（95% CI 24%至59%）和93%（95% CI 88%至97%）。五项研究中，233名患者的一年总生存率为59%（95% CI 53%至65%）。根据四项研究的数据，所有级别的不良事件中，皮疹（53%）、腹泻（45%）、甲溝炎（35%）、食欲减退（35%）和皮肤干燥（27%）的发生率均最高。我们的研究强调并证实了奥西美替尼治疗EGFR突变晚期NSCLC的LM具有显著的疗效和可控的安全性。© 2023. BioMed Central Ltd., 一部分Springer Nature.

The aim of this study was to evaluate the efficacy and safety of osimertinib for the treatment of leptomeningeal metastases (LM) from epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC).We conducted a systematic review and meta-analysis to aggregate the clinical outcomes of patients with LM from EGFR-mutant NSCLC treated with osimertinib. A comprehensive literature search for published and unpublished studies was implemented in April 2021 of PubMed, EMBASE, the Cochrane Library, and several international conference databases, in accordance with the PRISMA guidelines. Meta-analysis of proportions was conducted to calculate the pooled rate of overall response rate (ORR), disease control rate (DCR), one-year overall survival (OS), and adverse events (AEs).A total of eleven studies (five prospective and six retrospective) including 353 patients were included. The majority of patients (346/353, 98.0%) received osimertinib as ≥ 2nd-line treatment for LM, either at a dosage of 80 mg (161/353, 45.6%) or 160 mg (191/353, 54.1%). The pooled rates of ORR and DCR were 42% (95% CI 24% to 59%) and 93% (95% CI 88% to 97%), respectively. The pooled one-year OS rate was 59% (95% CI 53% to 65%) in 233 patients from five studies. The highest incidence of AEs of all grades was rash (53%), followed by diarrhea (45%), paronychia (35%), decreased appetite (35%), and dry skin (27%), based on data from four studies.Our study highlighted and confirmed the meaningful efficacy and a manageable safety profile of osimertinib for the treatment of LM from EGFR-mutant advanced NSCLC.© 2023. BioMed Central Ltd., part of Springer Nature.